Clinical Trial

A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Aprocitentan tablets are currently the only endothelin dual receptor antagonist approved internationally for the treatment of resistant hypertension.This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the efficacy and safety of aprocitentan tablets(SYH9108) in patients with treatment-resistant hypertension (rHTN)
Trial Details
NCT Number NCT07635914
Lead Sponsor CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Conditions Resistant Hypertension
Enrollment 382 participants
Start Date 2026-05-31
Primary Completion 2029-12-28 (estimated)
Study Completion 2030-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-09